Darwin Global Management, Ltd. - 27 Feb 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role: 10%+ Owner
Signature: Darwin Global Management, Ltd. By: /s/ John Legge, Director and Chief Financial Officer
Issuer symbol: N/A
Transactions as of: 27 Feb 2023
Net transactions value: +$24,094,937
Form type: 4
Filing time: 08 Mar 2023, 09:51:52 UTC
Previous filing: 08 Mar 2023
Next filing: 28 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMAM	American Depository Shares ("ADSs")	Purchase	$356,896	+65,127	+0.86%	$5.48	7,649,616	27 Feb 2023	Ordinary Shares	455,889	$0.000000	See footnotes	F1, F2, F3
transaction	AMAM	ADSs	Purchase	$240,541	+39,957	+0.52%	$6.02	7,689,573	28 Feb 2023	Ordinary Shares	279,699	$0.000000	See footnotes	F1, F2, F3
transaction	AMAM	ADSs	Purchase	$23,497,500	+3,615,000	+47%	$6.50	11,304,573	06 Mar 2023	Ordinary Shares	25,305,000	$0.000000	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each ADS represents 7 ordinary shares, par value $0.0001 per share ("Ordinary Shares").
F2	Securities held for the accounts of certain investment funds and accounts for which Darwin Global Management, Ltd. ("Darwin Global") acts as investment manager, including Darwin Global Master Fund, Ltd. ("Master Fund"). The sole shareholder of Darwin Global is controlled by Dr. Abhishek Trehan ("Dr. Trehan").
F3	For purposes of Section 16 of the Securities Exchange Act of 1934, each of Darwin Global, Master Fund and Dr. Trehan expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Darwin Global, Master Fund or Dr. Trehan is the beneficial owner of such securities for purposes of Section 16 or any other purpose.